
## Nam Ah Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3339219/publications.pdf Version: 2024-02-01



ΝΛΜΔΗΚΙΜ

#	Article	IF	CITATIONS
1	Polyamidoamine-Decorated Nanodiamonds as a Hybrid Gene Delivery Vector and siRNA Structural Characterization at the Charged Interfaces. ACS Applied Materials & Interfaces, 2017, 9, 31543-31556.	8.0	48
2	Effects of pH and Buffer Concentration on the Thermal Stability of Etanercept Using DSC and DLS. Biological and Pharmaceutical Bulletin, 2014, 37, 808-816.	1.4	31
3	Arginine as a protein stabilizer and destabilizer in liquid formulations. International Journal of Pharmaceutics, 2016, 513, 26-37.	5.2	31
4	Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties. PLoS ONE, 2014, 9, e96967.	2.5	30
5	Comparison of solubility enhancement by solid dispersion and micronized butein and its correlation with in vivo study. Journal of Pharmaceutical Investigation, 2021, 51, 53-60.	5.3	30
6	Process cycle development of freeze drying for therapeutic proteins with stability evaluation. Journal of Pharmaceutical Investigation, 2016, 46, 519-536.	5.3	29
7	Comprehensive evaluation of etanercept stability in various concentrations with biophysical assessment. International Journal of Pharmaceutics, 2014, 460, 108-118.	5.2	27
8	Biophysical stability of hyFc fusion protein with regards to buffers and various excipients. International Journal of Biological Macromolecules, 2016, 86, 622-629.	7.5	21
9	Preferential exclusion mechanism by carbohydrates on protein stabilization using thermodynamic evaluation. International Journal of Biological Macromolecules, 2018, 109, 311-322.	7.5	20
10	Enhanced intranasal insulin delivery by formulations and tumor protein-derived protein transduction domain as an absorption enhancer. Journal of Controlled Release, 2019, 294, 226-236.	9.9	16
11	Investigation of polymeric excipients for dutasteride solid dispersion and its physicochemical characterization. Archives of Pharmacal Research, 2014, 37, 214-224.	6.3	15
12	Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry. Archives of Pharmacal Research, 2016, 39, 668-676.	6.3	15
13	Fundamental analysis of recombinant human epidermal growth factor in solution with biophysical methods. Drug Development and Industrial Pharmacy, 2015, 41, 300-306.	2.0	14
14	Do not flick or drop off-label use plastic syringes in handling therapeutic proteins before administration. International Journal of Pharmaceutics, 2020, 587, 119704.	5.2	14
15	Evaluation of etanercept stability as exposed to various sugars with biophysical assessment. International Journal of Pharmaceutics, 2014, 476, 50-59.	5.2	13
16	Optimization of protein solution by a novel experimental design method using thermodynamic properties. Archives of Pharmacal Research, 2012, 35, 1609-1619.	6.3	11
17	Evaluation of protein formulation and its viscosity with DSC, DLS, and microviscometer. Journal of Pharmaceutical Investigation, 2014, 44, 309-316.	5.3	10
18	Evaluation of etanercept degradation under oxidative stress and potential protective effects of various amino acids. International Journal of Pharmaceutics, 2015, 492, 127-136.	5.2	10

Nам Ан Кім

#	Article	IF	CITATIONS
19	Solubility evaluation and thermodynamic modeling of β-lapachone in water and ten organic solvents at different temperatures. Fluid Phase Equilibria, 2018, 472, 1-8.	2.5	9
20	N-Acetylated-L-arginine (NALA) is an enhanced protein aggregation suppressor under interfacial stresses and elevated temperature for protein liquid formulations. International Journal of Biological Macromolecules, 2021, 166, 654-664.	7.5	9
21	3D-printed tablets using a single-step hot-melt pneumatic process for poorly soluble drugs. International Journal of Pharmaceutics, 2021, 595, 120257.	5.2	9
22	Evaluation of antioxidants in protein formulation against oxidative stress using various biophysical methods. International Journal of Biological Macromolecules, 2016, 82, 192-200.	7.5	8
23	Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models. International Journal of Pharmaceutics, 2021, 608, 121039.	5.2	8
24	Solubility Determination of c-Met Inhibitor in Solvent Mixtures and Mathematical Modeling to Develop Nanosuspension Formulation. Molecules, 2021, 26, 390.	3.8	7
25	Crystal Structure of DsbA from Corynebacterium diphtheriae and Its Functional Implications for CueP in Gram-Positive Bacteria. Molecules and Cells, 2015, 38, 715-722.	2.6	7
26	Basal buffer systems for a newly glycosylated recombinant human interferon-β with biophysical stability and DoE approaches. European Journal of Pharmaceutical Sciences, 2015, 78, 177-189.	4.0	6
27	Biophysical evaluation of hybrid Fc fusion protein of hGH to achieve basal buffer system. International Journal of Pharmaceutics, 2016, 513, 421-430.	5.2	6
28	Enhanced protein aggregation suppressor activity of N-acetyl-l-arginine for agitation-induced aggregation with silicone oil and its impact on innate immune responses. International Journal of Biological Macromolecules, 2022, 216, 42-51.	7.5	6
29	Rapid methodology for basal system selection of therapeutic proteins during the early stage biopharmaceutical development. Journal of Pharmaceutical Investigation, 2020, 50, 363-372.	5.3	5
30	Off-label use of plastic syringes with silicone oil for intravenous infusion bags of antibodies. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 166, 205-215.	4.3	5
31	Lessons Learned in Protein Precipitation Using a Membrane Emulsification Technique to Produce Reversible and Uniform Microbeads. Pharmaceutics, 2021, 13, 1738.	4.5	5
32	Chemical stability and in vitro and clinical efficacy of a novel hybrid retinoid derivative, bis-retinamido methylpentane. International Journal of Pharmaceutics, 2015, 495, 93-105.	5.2	4
33	New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC. Pharmaceutics, 2020, 12, 121.	4.5	4
34	Protein microbeadification to achieve highly concentrated protein formulation with reversible properties and in vivo pharmacokinetics after reconstitution. International Journal of Biological Macromolecules, 2021, 185, 935-948.	7.5	4
35	Mimicking Low pH Virus Inactivation Used in Antibody Manufacturing Processes: Effect of Processing Conditions and Biophysical Properties on Antibody Aggregation and Particle Formation. Journal of Pharmaceutical Sciences, 2021, 110, 3188-3199.	3.3	4
36	Correlation of Solubility Thermodynamics of Glibenclamide with Recrystallization and In Vitro Release Profile. Molecules, 2022, 27, 1392.	3.8	2

#	Article	IF	CITATIONS
37	Dissociation mechanics and stability of type A botulinum neurotoxin complex by means of biophysical evaluation. Journal of Pharmaceutical Investigation, 2022, 52, 453-463.	5.3	1